Julie Ehlers

Cancer Therapy Advisor

Cervical, Breast Cancer Screening Less Likely in Sexual Orientation and Gender Identity Minorities

By: Julie Ehlers

| Publish Date Sexual orientation or gender identity (SOGI) minority individuals are less likely than heterosexual or cisgender

Cancer Therapy Advisor

Metastasis-Directed Therapy Improves Survival in Oligometastatic CRPC

By: Julie Ehlers

| Publish Date Adding metastasis-directed therapy (MDT) to abiraterone acetate and androgen-deprivation therapy (ADT) leads to

Oncology Nurse Advisor

Cervical, Breast Cancer Screening Less Likely in Sexual Orientation and Gender Identity Minorities

By: Julie Ehlers

Arena L, Alizai Q, Elemosho A, Chatzipanagiotou OP, Pawlik TM. Sexual orientation and gender identity based disparities in colorectal, cervical, and breast cancer screening in the United States

Cancer Therapy Advisor

A Quarter of US Workers Want to Leave Their Jobs, But Stay for Health Insurance, Survey Suggests

By: Julie Ehlers

| Publish Date About 1 in 4 US workers (24%) experience “job lock,” meaning they would like to leave their jobs but stay due to fear

Cancer Therapy Advisor

Each Blistering Sunburn Increases Keratinocyte Carcinoma Risk by up to 8%

By: Julie Ehlers

| Publish Date Experiencing even 1 blistering sunburn increases an individual's risk for keratinocyte carcinoma (KC), including

Cancer Therapy Advisor

KRAS-Targeting Vaccine Appears Safe, Effective in Patients at High Risk for PDAC

By: Julie Ehlers

| Publish Date A first-in-human study of a peptide vaccine has shown safety and durable efficacy in patients at high risk of pancreatic

Oncology Nurse Advisor

Effect of Phytoestrogen Intake on Breast Cancer Risk May Depend on Subtype

By: Julie Ehlers

In this study, the researchers aimed to evaluate associations between dietary phytoestrogen intake and the risk of estrogen receptor (ER)-defined, progesterone receptor (PR)-defined, and HER2-defined breast cancers.

Cancer Therapy Advisor

STXBP2 Gene Variants May Affect CAR-T Toxicity in Patients With ‘Aggressive' Lymphoma

By: Julie Ehlers

| Publish Date In patients with “aggressive” lymphoma, the presence of STXBP2 gene variants can affect whether chimeric antigen

Cancer Therapy Advisor

Long-Term Hodgkin Lymphoma Survivors Have Increased Risk of All-Cause Mortality

By: Julie Ehlers

| Publish Date Patients who have survived Hodgkin lymphoma for at least 5 years have nearly twice the all-cause mortality rate of the general US population, according to findings published in JAMA Network Open

Hematology Advisor

Subcutaneous DISC-3405 Safely Lowers Phlebotomy Rates in Polycythemia Vera

By: Julie Ehlers

The mean number of phlebotomy events decreased from 4 events prior to dosing to 0.6 events for the 26 weeks following start of treatment.